Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Q702 |
Trade Name | |
Synonyms | Q 702|Q-702 |
Drug Descriptions |
Q702 selectively inhibits Axl, Mertk, and Csf1r, which may relieve immunosuppression in the tumor microenvironment and increase infiltration of immune cells into tumors, potentially leading to tumor regression (AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 4974) |
DrugClasses | AXL Inhibitor 30 CSF1R Inhibitor 28 MERTK Inhibitor 13 |
CAS Registry Number | NA |
NCIT ID | C177458 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Azacitidine + Q702 + Venetoclax | Azacitidine Q702 Venetoclax | 0 | 1 |
Pembrolizumab + Q702 | Pembrolizumab Q702 | 0 | 1 |
Q702 | Q702 | 0 | 1 |